A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

PHASE1TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Spinocerebellar Ataxia Type 3
Interventions
DRUG

BIIB132

Administered as specified in the treatment arm

DRUG

BIIB132-Matching Placebo

Administered as specified in the treatment arm

Trial Locations (20)

10032

Columbia Univeristy Medical Center, New York

19107

Pennsylvania Neurological Institute, Philadelphia

32610

University of Florida, Center for Movement Disorders, Gainesville

33612

Movement Disorder Center Florida, Tampa

45122

Universitaetsklinikum Essen Klinik für Neurologie, Essen

53127

Deutsches Zentrum fuer Neurodegenerative Erkrankungen (DZNE), Bonn

63110

Washington University, St Louis

72076

UniversitaetsklinikumTübingen Neurologische Universitätsklinik, Tübingen

77030

Houston Methodist Research Institute, Houston

90035

University of California - Los Angeles, Los Angeles

94143

University of California San Francisco, San Francisco

98195

University of Washington, Seattle

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

02114

Massachusetts General Hospital, Boston

9713 AG

Universitair Medisch Centrum Groningen (UMCG), Groningen

6525 GA

Radboudumc, Nijmegen

1649-035

Centro Hospitalar de Lisboa Norte, Lisbon

4099-001

Centro Hospitalar do Porto, Porto

WC1N 3BG

University College London Hospital (UCLH), London

OX3 7LJ

Churchill Hospital, Oxford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT05160558 - A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3 | Biotech Hunter | Biotech Hunter